Fort Washington Investment Advisors Inc. OH Increases Stake in Haemonetics Co. (NYSE:HAE)

Fort Washington Investment Advisors Inc. OH lifted its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 88.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 517,086 shares of the medical instruments supplier's stock after buying an additional 242,956 shares during the quarter. Fort Washington Investment Advisors Inc. OH owned about 1.03% of Haemonetics worth $32,861,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of HAE. TD Waterhouse Canada Inc. purchased a new stake in shares of Haemonetics during the 4th quarter valued at approximately $25,000. Covestor Ltd lifted its stake in shares of Haemonetics by 146.8% during the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after buying an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new stake in shares of Haemonetics during the 4th quarter valued at approximately $62,000. Parkside Financial Bank & Trust lifted its stake in shares of Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 240 shares in the last quarter. Finally, AlphaQuest LLC lifted its stake in shares of Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock valued at $143,000 after buying an additional 1,826 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on HAE shares. Raymond James reaffirmed a "strong-buy" rating and set a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Wall Street Zen lowered shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a report on Tuesday, May 20th. Finally, Needham & Company LLC decreased their target price on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $97.89.

Haemonetics Price Performance

Shares of NYSE:HAE traded down $1.34 during trading on Friday, reaching $70.02. The company had a trading volume of 289,017 shares, compared to its average volume of 677,894. The company has a fifty day moving average of $65.16 and a two-hundred day moving average of $69.04. The stock has a market capitalization of $3.36 billion, a P/E ratio of 27.57, a price-to-earnings-growth ratio of 1.11 and a beta of 0.36. Haemonetics Co. has a 12 month low of $55.30 and a 12 month high of $94.99. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. The firm had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.90 EPS. Equities research analysts forecast that Haemonetics Co. will post 4.55 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.